DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Monday morning. The firm issued a hold rating on the stock.

Separately, JMP Securities reaffirmed a “market outperform” rating and set a $10.00 price objective on shares of DBV Technologies in a research note on Friday, January 10th.

DBV Technologies Stock Performance

Shares of DBVT opened at $7.07 on Monday. The stock has a 50 day moving average price of $4.99 and a 200 day moving average price of $4.09. The stock has a market capitalization of $145.42 million, a price-to-earnings ratio of -1.57 and a beta of -0.08. DBV Technologies has a one year low of $2.20 and a one year high of $8.50.

Institutional Trading of DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned about 0.24% of DBV Technologies as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.